Mealey's (February 6, 2019, 1:57 PM EST) -- WASHINGTON, D.C. — A final written decision by the Patent Trial and Appeal Board that invalidated various claims of a patented prostate cancer treatment was vacated and remanded Feb. 5 by the Federal Circuit U.S. Court of Appeals (Sanofi Mature IP v. Mylan Laboratories Limited, No. 18-1203, Fed. Cir., 2019 U.S. App. LEXIS 3529)....